Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Rhea-AI Summary

Daxor (Nasdaq: DXR) announced the launch of an outpatient Blood Volume Analysis (BVA™) program at a leading healthcare facility in eastern Kansas, expanding its Midwestern outpatient footprint. The program uses Daxor’s turnkey ezBVA Lab CLIA-certified send-out model to deliver 98% accurate, quantitative blood, plasma, and red cell volume measurements within 24 hours without capital equipment or dedicated lab infrastructure.

According to Daxor, the service is designed to replace subjective fluid assessment with objective volume metrics, supporting individualized decongestion strategies that aim to optimize outcomes, safeguard renal function, and reduce hospital readmissions within existing reimbursement structures.

Positive

• Outpatient BVA program launched at a leading Kansas healthcare facility
• ezBVA Lab send-out model delivers 98% accurate blood volume results in 24 hours
• No capital equipment or dedicated lab infrastructure required for participating practices

Negative

• None.

Market Context

The platform history recorded 5.39% and 2.31% 24-hour moves for prior adoption announcements. This l...

Analysis

The platform history recorded 5.39% and 2.31% 24-hour moves for prior adoption announcements. This launch extends that theme; reimbursement execution and repeatability of outpatient service use remain key factors to watch.

Key Figures

Measurement accuracy: 98% Turnaround time: 24 hours Capital equipment requirement: zero

3 metrics

Measurement accuracy 98% ezBVA Lab send-out model

Turnaround time 24 hours Outpatient blood volume measurements

Capital equipment requirement zero ezBVA Lab send-out model

Historical Context

5 past events · Latest: Jul 07 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 07	Conference exhibition	Neutral	-0.3%	First-time exhibition announcement for Dysautonomia International Conference
Jun 02	Patent issuance	Positive	+2.9%	U.S. patent granted for remote blood volume monitoring technology
Apr 28	Commercial adoption	Positive	+5.4%	MedAxiom forum supported commercial adoption of Blood Volume Analysis
Apr 08	Customer expansion	Positive	+2.3%	New BVA program launched at high-volume Ohio cardiology center
Mar 26	Clinical data	Positive	-2.9%	BVA metric showed higher specificity for detecting capillary leak

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior commercial adoption announcements aligned with positive price reactions, while conference and clinical-data updates diverged.

Key Terms

clia-certified, blood volume analysis, hypervolemia

3 terms

clia-certified regulatory

"The launch leverages Daxor’s turnkey ezBVA Lab send-out model"

CLIA-certified means a laboratory has passed U.S. federal standards for performing tests on human samples, showing its results are accurate, reliable and timely. For investors this matters because certification is often required to sell clinical test services, bill insurers, win hospital or physician partnerships and avoid regulatory penalties — much like a restaurant passing a health inspection or a car getting a safety sticker before it can be sold.

blood volume analysis medical

"new outpatient Blood Volume Analysis (BVA™) program"

A clinical test that measures how much blood a person has and how it is distributed between plasma and red cells, often using tracers or dyes and mathematical calculations. Think of it like measuring how much water is in different compartments of a tank to understand whether there is too much or too little; this information can affect drug dosing, treatment decisions, clinical trial endpoints, and the market value of diagnostics or therapies tied to fluid-management conditions.

hypervolemia medical

"leaves subclinical hypervolemia unaddressed"

Excess fluid in the blood and body tissues that occurs when the body retains more water and salt than it can remove, often seen with heart, kidney, or liver problems or after too much intravenous fluid. Like overfilling a balloon, it raises blood volume and pressure and can cause swelling, shortness of breath, and strain on organs. It matters to investors because it can affect clinical trial safety results, regulatory reviews, hospital costs, product labeling, and potential liability tied to drugs, devices, or treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model

OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced the launch of a new outpatient Blood Volume Analysis (BVA^™) program at a leading healthcare facility in eastern Kansas. This initiative expands Daxor’s presence in Midwestern outpatient care, giving regional clinicians direct access to objective volume metrics.

The launch leverages Daxor’s turnkey ezBVA Lab send-out model, enabling outpatient practices to obtain 98% accurate, quantitative blood volume measurements within 24 hours—with zero capital equipment or dedicated lab infrastructure required. By directly measuring total blood, plasma, and red cell volume, clinicians can replace subjective fluid estimation with precise, data-backed decongestion strategies that optimize patient outcomes and prevent readmissions through existing reimbursement structures.

Executive Commentary

“Expanding access to outpatient precision diagnostics is critical to breaking the costly cycle of readmissions. Our turnkey ezBVA Lab service eliminates capital and logistical hurdles, allowing high-volume cardiology centers to seamlessly integrate individualized decongestion care that improves outcomes while lowering overall system costs.”
— Michael Feldschuh, President and CEO of Daxor Corporation

“Relying on clinical estimates for fluid management routinely leaves subclinical hypervolemia unaddressed or leads to over-diuresis. BVA delivers diagnostic accuracy, giving physicians the objective clarity needed to fine-tune therapies, safeguard renal function, and improve opportunities to keep patients safely out of the hospital.”
— John L. Jefferies, MD, MPH, MBA, Chief Medical Officer of Daxor Corporation

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.

For more information, please visit our website at Daxor.com.

Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com

FAQ

What did Daxor (DXR) announce on July 29, 2026 about its ezBVA Lab service?

Daxor announced a new outpatient Blood Volume Analysis program using its ezBVA Lab send-out model at a leading healthcare facility in eastern Kansas. According to Daxor, this expands its Midwestern outpatient presence and provides clinicians rapid, quantitative blood volume measurements without capital equipment investment.

How does Daxor’s ezBVA Lab blood volume test work for outpatient clinics using DXR services?

Daxor’s ezBVA Lab model lets outpatient practices send samples to a CLIA-certified lab and receive quantitative blood, plasma, and red cell volume results within 24 hours. According to Daxor, the service requires no dedicated lab infrastructure or capital equipment at the clinic site.

What diagnostic accuracy does Daxor (DXR) report for its BVA test in the new Kansas program?

Daxor reports that its Blood Volume Analysis provides 98% accurate quantitative blood volume measurements through the ezBVA Lab model. According to Daxor, this accuracy helps replace subjective fluid estimates with objective data to guide decongestion strategies and protect renal function in outpatient care.

How could Daxor’s new outpatient BVA program impact hospital readmissions for DXR-related care?

Daxor states that objective blood volume metrics from BVA can help optimize decongestion therapies and prevent avoidable readmissions. According to Daxor, integrating ezBVA Lab into high-volume cardiology centers supports safer fluid management while working within existing reimbursement structures in outpatient settings.

Why is Daxor expanding its Blood Volume Analysis footprint into eastern Kansas outpatient settings?

Daxor is expanding into eastern Kansas to broaden access to outpatient precision diagnostics and objective volume metrics. According to Daxor, this regional expansion supports clinicians in managing fluid status more precisely, potentially improving outcomes and lowering overall system costs tied to heart failure readmissions.

What clinical benefits does Daxor (DXR) highlight for its BVA test in managing fluid status?

Daxor highlights that BVA helps identify subclinical hypervolemia and avoid over-diuresis by measuring total blood, plasma, and red cell volume. According to Daxor, this objective clarity supports fine-tuning therapies, safeguarding renal function, and keeping appropriate patients safely out of the hospital.